Relmada Therapeutics Inc (RLMD) Stock Price, Quote & News

Company Profile

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessiv...

Industry: Biotechnology

Sector: Healthcare

Phone: 786 629 1376

Website: www.relmada.com

Address:

2222 Ponce de Leon Blvd., Floor 3, Coral Gables, United States

MarketBeat May. 13 at 2:08 AM

https://marketbeat.com/a/8651231/ $RLMD Relmada Therapeutics Q1 Earnings Call Highlights

0 · Reply

teaman60 May. 12 at 11:56 PM

$RLMD Unknown, unfollowed company with superior drugs in its pipeline.

1 · Reply

EarningsInsider May. 12 at 9:32 PM

https://www.marketbeat.com/earnings/reports/2026-5-12-relmada-therapeutics-inc-stock/ $RLMD Relmada Therapeutics Earnings Transcript

0 · Reply

StocktwitsEarnings May. 12 at 9:09 PM

$RLMD Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.22 up 62.07% YoY • Relmada Therapeutics expects its $234.0 million cash balance as of March 31, 2026, to fund operations through 2029, including NDV-01 Phase 3 completion, and is on track to initiate the Phase 3 program in mid-2026.

0 · Reply

teaman60 Apr. 27 at 3:18 PM

$RLMD Gas a real problem with being over $7

2 · Reply

teaman60 Apr. 21 at 2:13 PM

$RLMD Someone dumping shares today. They are doing it slowly to get the most they can.

0 · Reply

teaman60 Apr. 21 at 1:45 PM

$RLMD Rug pull? If trials go bad this is gone.

0 · Reply

shehww Apr. 20 at 10:23 AM

$RLMD 😎 🔥🔥🔥

0 · Reply

VikaDelic Apr. 16 at 7:05 PM

$RLMD teamaam is all hyped up today, probably the day to add. Cheers brothers

1 · Reply

teaman60 Apr. 16 at 5:36 PM

$RLMD Strange no one follows this ticker. Good news if the get FDA approval for me I suppose

0 · Reply

Relmada Therapeutics files automatic mixed securities shelf

May 12, 2026, 4:30 PM EDT - 1 day ago

Relmada Therapeutics Earnings Call Transcript: Q1 2026

May 12, 2026, 4:05 PM EDT - 1 day ago

Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

May 6, 2026, 7:00 AM EDT - 7 days ago

Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026

May 5, 2026, 7:00 AM EDT - 8 days ago

Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026

2026-03-24T09:00:12.000Z - 7 weeks ago

Relmada Therapeutics initiated with an Overweight at Piper Sandler

2026-03-20T11:37:53.000Z - 7 weeks ago

Relmada Therapeutics price target raised to $19 from $10 at Mizuho

Mar 19, 2026, 4:30 PM EDT - 7 weeks ago

Relmada Therapeutics Earnings Call Transcript: Q4 2025

Mar 19, 2026, 4:01 PM EDT - 7 weeks ago

Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

Mar 12, 2026, 7:00 AM EDT - 2 months ago

Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026

Mar 10, 2026, 8:40 AM EDT - 2 months ago

Relmada Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 4:30 PM EDT - 2 months ago

Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference

2026-03-09T12:00:38.000Z - 2 months ago

Why Is Relmada Therapeutics Stock (RLMD) Up Today?

2026-03-09T11:30:59.000Z - 2 months ago

Relmada Therapeutics prices 29.47M shares at $4.75 in private placement

2026-03-09T11:15:52.000Z - 2 months ago

Relmada Therapeutics reports 12-month Phase 2 interim data for NDV-01

Mar 9, 2026, 7:05 AM EDT - 2 months ago

Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing

Mar 9, 2026, 7:00 AM EDT - 2 months ago

Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer

2026-03-02T11:38:48.000Z - 2 months ago

Relmada Therapeutics initiated with a Buy at Lucid Capital

2026-01-23T11:25:12.000Z - 3 months ago

Relmada Therapeutics assumed at Outperform from Market Perform at Leerink

2026-01-12T12:16:48.000Z - 4 months ago

Relmada Therapeutics provides regulatory update on FDA alignment for NDV-01

Jan 12, 2026, 7:00 AM EST - 4 months ago

Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications

2025-12-22T00:10:11.000Z - 5 months ago

Relmada Therapeutics initiated with a Buy at Jefferies

2025-12-03T12:35:52.000Z - 5 months ago

Relmada Therapeutics to present NDV-01 Phase 2 data at SUO meeting

Dec 3, 2025, 7:30 AM EST - 5 months ago

Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology

2025-11-19T13:40:55.000Z - 6 months ago

Mizuho upgrades Relmada to Outperform with ‘more upside’ ahead

2025-11-19T13:35:38.000Z - 6 months ago

Relmada Therapeutics upgraded to Outperform from Neutral at Mizuho

Nov 13, 2025, 4:30 PM EST - 6 months ago

Relmada Therapeutics Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:01 PM EST - 6 months ago

Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates

Nov 7, 2025, 7:30 AM EST - 6 months ago

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025

2025-11-04T12:50:53.000Z - 6 months ago

Relmada Therapeutics announces FDA feedback on study paths for NDV-01

2025-11-04T12:50:30.000Z - 6 months ago

Relmada Therapeutics prices 40.1M shares at $2.20 in underwritten offering

Nov 4, 2025, 7:09 AM EST - 6 months ago

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Nov 4, 2025, 7:01 AM EST - 6 months ago

Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer

2025-10-07T11:41:16.000Z - 7 months ago

Relmada Therapeutics appoints Max Kates to clincal advisory board

Oct 7, 2025, 7:30 AM EDT - 7 months ago

Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01

Sep 18, 2025, 10:00 AM EDT - 8 months ago

Relmada Therapeutics Transcript: Small-Cap Virtual Conference

2025-09-16T13:10:54.000Z - 8 months ago

Relmada Therapeutics regains compliance with Nasdaq min bid price requirement

Sep 16, 2025, 9:00 AM EDT - 8 months ago

Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sep 10, 2025, 7:15 AM EDT - 8 months ago

Relmada Issues Mid-Year CEO Letter to Shareholders

Aug 7, 2025, 4:30 PM EDT - 9 months ago

Relmada Therapeutics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:05 PM EDT - 9 months ago

Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC

Jul 31, 2025, 7:00 AM EDT - 10 months ago

Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

Jul 15, 2025, 8:00 AM EDT - 10 months ago

Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01

Jul 9, 2025, 8:00 AM EDT - 11 months ago

DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors

Jun 17, 2025, 7:00 AM EDT - 11 months ago

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology

May 12, 2025, 4:30 PM EDT - 1 year ago

Relmada Therapeutics Earnings Call Transcript: Q1 2025

May 12, 2025, 4:01 PM EDT - 1 year ago

Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 7:30 AM EDT - 1 year ago

Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Apr 28, 2025, 4:30 PM EDT - 1 year ago

Relmada Therapeutics Transcript: Status Update

Apr 28, 2025, 1:38 PM EDT - 1 year ago

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

Apr 27, 2025, 9:00 AM EDT - 1 year ago

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data

Apr 14, 2025, 7:30 AM EDT - 1 year ago

Relmada Therapeutics To Present NDV-01 Data at AUA2025

Mar 27, 2025, 4:30 PM EDT - 1 year ago

Relmada Therapeutics Earnings Call Transcript: Q4 2024

Mar 27, 2025, 4:05 PM EDT - 1 year ago

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Mar 26, 2025, 9:00 AM EDT - 1 year ago

Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025

Mar 25, 2025, 7:30 AM EDT - 1 year ago

Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.

Feb 6, 2025, 7:30 AM EST - 1 year ago

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB

Dec 9, 2024, 8:11 AM EST - 1 year ago

Relmada discontinues late-stage trials for depression drug, explores sale

Dec 9, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017

Dec 4, 2024, 8:00 AM EST - 1 year ago

Relmada's depression drug unlikely to meet main trial goal, analysis shows

Dec 4, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance

Nov 21, 2024, 1:34 PM EST - 1 year ago

Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm

Nov 20, 2024, 7:00 AM EST - 1 year ago

Relmada Therapeutics Transcript: Jefferies London Healthcare Conference

Nov 14, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease

Nov 7, 2024, 4:32 PM EST - 1 year ago

Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 7, 2024, 4:30 PM EST - 1 year ago

Relmada Therapeutics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 4:30 PM EST - 1 year ago

Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

Aug 7, 2024, 4:30 PM EDT - 1 year ago

Relmada Therapeutics Earnings Call Transcript: Q2 2024

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 5, 2024, 7:30 AM EDT - 1 year ago

Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024

MarketBeat May. 13 at 2:08 AM

https://marketbeat.com/a/8651231/ $RLMD Relmada Therapeutics Q1 Earnings Call Highlights

0 · Reply

teaman60 May. 12 at 11:56 PM

$RLMD Unknown, unfollowed company with superior drugs in its pipeline.

1 · Reply

EarningsInsider May. 12 at 9:32 PM

https://www.marketbeat.com/earnings/reports/2026-5-12-relmada-therapeutics-inc-stock/ $RLMD Relmada Therapeutics Earnings Transcript

0 · Reply

StocktwitsEarnings May. 12 at 9:09 PM

0 · Reply

teaman60 Apr. 27 at 3:18 PM

$RLMD Gas a real problem with being over $7

2 · Reply

teaman60 Apr. 21 at 2:13 PM

$RLMD Someone dumping shares today. They are doing it slowly to get the most they can.

0 · Reply

teaman60 Apr. 21 at 1:45 PM

$RLMD Rug pull? If trials go bad this is gone.

0 · Reply

shehww Apr. 20 at 10:23 AM

$RLMD 😎 🔥🔥🔥

0 · Reply

VikaDelic Apr. 16 at 7:05 PM

$RLMD teamaam is all hyped up today, probably the day to add. Cheers brothers

1 · Reply

teaman60 Apr. 16 at 5:36 PM

$RLMD Strange no one follows this ticker. Good news if the get FDA approval for me I suppose

0 · Reply

teaman60 Apr. 16 at 2:49 PM

$RLMD Think about setting a stop loss on this. If bad news, it will tank to $2

0 · Reply

teaman60 Apr. 15 at 4:56 PM

$RLMD Can't hold 7s,as I said it wouldn't

0 · Reply

OfficialStocktwitsUser Apr. 14 at 4:58 PM

$RLMD RSI: 70.17, MACD: 0.5248 Vol: 0.50, MA20: 6.72, MA50: 5.45 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply